Novo Nordisk A/S (NVO)

NYSE: NVO · IEX Real-Time Price · USD
-1.50 (-1.22%)
Feb 27, 2024, 12:44 PM EST - Market open
Market Cap 551.40B
Revenue (ttm) 34.41B
Net Income (ttm) 12.40B
Shares Out 4.46B
EPS (ttm) 2.71
PE Ratio 45.62
Forward PE 37.31
Dividend $0.66 (0.54%)
Ex-Dividend Date Mar 22, 2024
Volume 4,824,511
Open 119.97
Previous Close 123.49
Day's Range 119.79 - 122.13
52-Week Range 67.66 - 124.87
Beta 0.18
Analysts Strong Buy
Price Target 100.10 (-17.95%)
Earnings Date Jan 31, 2024

About NVO

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1923
Employees 64,319
Stock Exchange NYSE
Ticker Symbol NVO
Full Company Profile

Financial Performance

In 2023, Novo Nordisk's revenue was 232.26 billion, an increase of 31.26% compared to the previous year's 176.95 billion. Earnings were 83.68 billion, an increase of 50.71%.

Financial numbers in DKK Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for NVO stock is "Strong Buy." The 12-month stock price forecast is $100.1, which is a decrease of -17.95% from the latest price.

Price Target
(-17.95% downside)
Analyst Consensus: Strong Buy
Stock Forecasts


Zealand's obesity drug shouldn't disrupt Novo Nordisk-Eli Lilly leadership: Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Fast Money' to talk obesity drugmakers after a new study out of Zealand Pharma analyzed the impact of GLP-1s on liver disease.

Other symbols: LLY
18 hours ago - CNBC Television

These 2 carnivore dining stocks gaining on the Ozempic craze

The Ozempic and GLP-1 weight loss trend parallels the artificial intelligence (AI) mania that's gone mainstream viral, sending stocks like Novo Nordisk A/S NYSE: NVO and Nvidia Corp. NASDAQ: NVDA thro...

Other symbols: NVDA
1 day ago - MarketBeat

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 26 February 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Coun...

1 day ago - GlobeNewsWire

Novo Nordisk and Eli Lilly rival soars 26% after promising weight-loss drug results

Zealand Pharma's Phase 2 trial was an "uniquivocal win" for a drug that can treat both liver disease and obesity, analysts said.

Other symbols: LLY
1 day ago - CNBC

Europe's megacap appeal stokes stocks to record highs

Growing demand for megacap stocks that tap global secular growth trends has catapulted European shares to fresh highs, although some say their star may wane as investors seek value elsewhere.

Other symbols: ASMLLVMUY
5 days ago - Reuters

Notice for the Annual General Meeting of Novo Nordisk A/S

Bagsværd, Denmark, 21 February 2024 – The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 21 March 2024 at 14.00 (CET) The Annual General Meeting is held as a partially electronic...

6 days ago - GlobeNewsWire

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 19 February 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Coun...

8 days ago - GlobeNewsWire

Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology

BARCELONA, Spain--(BUSINESS WIRE)--Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, announced today that it has entered into an exclusive license agreement w...

8 days ago - Business Wire

Eli Lilly, Novo Nordisk get growth stock status on weight-loss drug boost

U.S.-based Eli Lilly and Denmark's Novo Nordisk have struck gold with their weight-loss drugs, sending their shares to stratospheric levels and putting them on par with some high-growth tech stocks.

Other symbols: LLY
10 days ago - Reuters

Novo Nordisk CEO says food execs are ‘scared' of weight loss drug threat

The feverish craze for Wegovy, Ozempic and other GLP-1 drugs is not over. It is prompting food executives to call the top boss at Novo Nordisk to ask for advice.

11 days ago - Fox Business

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 14 February 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated per...

13 days ago - GlobeNewsWire

Goldman Sachs Says 'GRANOLAS' Stocks Are Set to Enjoy Further Gains

Large-cap European firms with a global footprint and strong balance sheets have outperformed the 'Magnificent Seven' US stocks and are poised for further gains, according to Sharon Bell, senior Europe...

14 days ago - Bloomberg Markets and Finance

Nervous About Nvidia, Tesla and the Magnificent 7? Look at Goldman's GRANOLAS.

Some of the biggest European stocks offer a better risk-adjusted return than the Magnificent 7, and that's not their only quality.

15 days ago - Barrons

This grouping of stocks has actually kept up with the Magnificent Seven, and with a lot less risk

For all the attention paid to the highflying tech giants dubbed the Magnificent Seven, there's another grouping that has kept right up with them, and with a lot lower risk.

15 days ago - Market Watch

Novo Nordisk's controlling shareholder plans to invest up to $7 bln a year by 2030 - FT

Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk , plans to invest up to $7 billion annually by 2030, the Financial Times reported on Monday.

15 days ago - Reuters

Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that

Novo Nordisk and Eli Lilly have given positive supply updates, aiming to reassure investors that they can continue to capitalize on the success of their drugs.

Other symbols: LLY
17 days ago - CNBC

Catalent Q2 sales inch past estimates amid takeover by Novo Holdings

Catalent reported second-quarter revenue slightly above Wall Street estimates on Friday, days after the contract drug manufacturer agreed to a $16.5-billion acquisition offer from Novo Nordisk's paren...

Other symbols: CTLT
18 days ago - Reuters

Novo Nordisk CEO on Catalent, Ozempic and Wegovy

Novo Nordisk A/S CEO Lars Fruergaard Jorgensen discusses the company's acquisition of Catalent for for $16.5 billion and the production of its weight-loss drug Wegovy and diabetes treatment Ozempic. F...

Other symbols: CTLT
19 days ago - Bloomberg Markets and Finance

US FDA finds control lapses at Catalent plant being sold to Novo

U.S. drug regulators in November found quality control lapses at the Bloomington, Indiana factory of contract drug manufacturer Catalent , including discovery of a "pest" on the manufacturing line, ac...

Other symbols: CTLT
20 days ago - Reuters

Healthy Returns: Novo Nordisk, Eli Lilly are tackling weight loss drug supply woes

Novo Nordisk and Eli Lilly are working to increase supply of their popular weight loss drugs. Meanwhile, the implantable neurotechnology field is heating up.

Other symbols: LLY
20 days ago - CNBC

Bio-pharma services are key to our strategy: Novo Holdings CEO

Kasim Kutay, CEO of Novo Holdings, discusses Novo Holdings acquisition of U.S.-based medicines manufacturer Catalent.

21 days ago - CNBC International TV

Novo Holdings invests in hospital chain Manipal in India

Novo Holdings, the holding company of Novo Nordisk , said on Tuesday it was investing in Indian private hospital chain Manipal Hospitals, its largest investment in Asia to date.

21 days ago - Reuters

Novo Nordisk Makes the Latest Big Pharma Deal. Why More Are Coming.

Big drug companies have substantial free cash flow from older, cash-cow drugs, manageable debt burdens, and investor pressure to find new growth opportunities.

22 days ago - Barrons

Novo Nordisk Parent Buys Catalent in $16.5 Billion Cash Deal

Shares of syringe maker Catalent (CTLT) soared 10% in early trading after it signed a deal to be sold to the controlling shareholder of Novo Nordisk (NVO) for $16.5 billion.

Other symbols: CTLT
22 days ago - Investopedia

Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply

Catalent is the main supplier of fill-finish work, which involves filling and packaging syringes and injection pens, for Novo Nordisk's Wegovy.

Other symbols: CTLT
22 days ago - CNBC